Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Effect of peroxisome proliferator-activated receptor gamma agonists examined
May 26th, 2005
Researchers explored the mechanism that underlies the effect of peroxisome proliferator-activated receptor-gamma (PPAR gamma) agonists. "In light of the clinical relevance of targeting cyclin D1 in breast cancer, we have investigated the mechanism underlying the effect of the PPAR gamma agonists troglitazone and ciglitazone on cyclin D1 repression," scientists in the United States reported. "We obtain evidence that the ability of high doses of troglitazone and ciglitazone to repress cyclin D1 is independent of PPAR gamma activation. PPAR gamma-inactive troglitazone and ciglitazone analogs...
Source: Women's Health Weekly (2005-05-26)
|
